4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      SERPINA1 modulates expression of amyloidogenic transthyretin.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hereditary transthyretin amyloidosis (ATTR) is caused by amyloid deposition of misfolded transthyretin (TTR) in various tissues. Recently, reduction of circulating serum TTR, achieved via silencing oligonucleotides, was introduced as therapy of ATTR amyloidosis. We explored the impact of Serpin Family A Member 1 (SERPINA1) on TTR mRNA and protein expression. Oncostatin M (OSM) induced SERPINA1 in hepatoma cells and mice, while concomitantly TTR expression was significantly reduced. SERPINA1 knockdown resulted in specific elevated TTR expression in hepatoma cells; however other genes belonging to the group of acute phase proteins were unaffected. In mice, serum TTR was elevated after mSERPINA1 knockdown throughout antisense treatment. Following SERPINA1 knockdown, TTR deposition in several tissues, including dorsal root ganglia and intestine, was found to be increased, however numbers did not exceed significance levels. The data suggest that SERPINA1 is a co-factor of TTR expression. Our findings provide novel insight in the regulation of TTR and reveal a role of SERPINA1 in the pathogenesis of ATTR amyloidosis.

          Related collections

          Author and article information

          Journal
          Exp Cell Res
          Experimental cell research
          Elsevier BV
          1090-2422
          0014-4827
          October 15 2020
          : 395
          : 2
          Affiliations
          [1 ] Medizinische Klinik B für Gastroenterologie und Hepatologie, Universitätsklinikum Münster, Münster, Germany.
          [2 ] i3S - Instituto de Investigação e Inovação em Saúde, IBMC - Instituto de Biologia Molecular e Celular,and ICBAS - Instituto de Ciências Biomédicas de Abel Salazar, Universidade do Porto, Porto, Portugal.
          [3 ] Ionis Pharmaceuticals, Carlsbad, CA, USA.
          [4 ] Medizinische Klinik B für Gastroenterologie und Hepatologie, Universitätsklinikum Münster, Münster, Germany. Electronic address: andree.zibert@ukmuenster.de.
          Article
          S0014-4827(20)30466-3
          10.1016/j.yexcr.2020.112217
          32768500
          903bd966-a1bd-4d59-ab00-2b015ac34763
          Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
          History

          ATTR amyloidosis,Alpha-1-antitrypsin,Antisense oligonucleotide,Disease modeling,Oncostatin M

          Comments

          Comment on this article